Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / Common Stock - $0.001 par value
-
Shares outstanding
-
128M
-
Number of holders
-
151
-
Total 13F shares, excl. options
-
80M
-
Shares change
-
+504K
-
Total reported value, excl. options
-
$277M
-
Value change
-
+$1.87M
-
Number of buys
-
79
-
Number of sells
-
-77
-
Price
-
$3.47
Significant Holders of Cytek Biosciences, Inc. - Common Stock - $0.001 par value (CTKB) as of Q3 2025
175 filings reported holding CTKB - Cytek Biosciences, Inc. - Common Stock - $0.001 par value as of Q3 2025.
Cytek Biosciences, Inc. - Common Stock - $0.001 par value (CTKB) has 151 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 80M shares
of 128M outstanding shares and own 62.5% of the company stock.
Largest 10 shareholders include BlackRock, Inc. (16.5M shares), Topline Capital Management, LLC (6.94M shares), VANGUARD GROUP INC (6.93M shares), HHLR ADVISORS, LTD. (6.66M shares), BROWN CAPITAL MANAGEMENT LLC (4.96M shares), STATE STREET CORP (4.08M shares), MILLENNIUM MANAGEMENT LLC (3.42M shares), DIMENSIONAL FUND ADVISORS LP (3.22M shares), GEODE CAPITAL MANAGEMENT, LLC (2.78M shares), and WELLINGTON MANAGEMENT GROUP LLP (2.54M shares).
This table shows the top 151 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.